Xencor (Xencor) Risk Assessment

View and export this data going back to 2013. Start your Free Trial

What is Xencor Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Xencor is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Xencor's Risk Assessment

For the Biotechnology subindustry, Xencor's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xencor's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Xencor's Risk Assessment falls into.

Xencor (NAS:XNCR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Xencor Risk Assessment Related Terms

Thank you for viewing the detailed overview of Xencor's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Xencor (Xencor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

XE9:Germany

Address

111 West Lemon Avenue, Monrovia, CA, USA, 91016

Website

http://www.xencor.com

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Executives

Bassil I Dahiyat	director, officer: PRESIDENT & CEO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke	director	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang	officer: SR. VICE PRESIDENT & CMO	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Celia Eckert	officer: VP, GENERAL COUNSEL	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais	officer: SR. VICE PRESIDENT & CSO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John J Kuch	officer: SR. VICE PRESIDENT & CFO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Richard J Ranieri	director	3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal	director	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Alan Bruce Montgomery	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Kevin Charles Gorman	director	12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Stafford John S Iii	10 percent owner	230 SOUTH LASALLE STREET 400, CHICAGO IL 60604